Indiara Brusco

Dr. Indiara Brusco


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2020 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
EGElaine Gonçalves
Elaine Gonçalves
GVGraziela Vieira
Graziela Vieira
TGTainara R. Gonçalves
Tainara R. Gonçalves
RSRóli R. Simões
Róli R. Simões
IBIndiara Brusco
Indiara Brusco
Rafael Cypriano DutraRafael Cypriano Dutra
Rafael Cypriano Dutra

1 March 2020 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
GBGabriela Becker
Gabriela Becker
IBIndiara Brusco
Indiara Brusco
RCRosana Casoti
Rosana Casoti
MMMarila Crivellaro Lay Marchiori
Marila Crivellaro Lay Marchiori
Letícia CruzLetícia Cruz
Letícia Cruz
SOSara Marchesan Oliveira
Sara Marchesan Oliveira

1 September 2020 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SKSabrina Qader Kudsi
Sabrina Qader Kudsi
CACaren Antoniazzi
Caren Antoniazzi
CCCamila Camponogara
Camila Camponogara
EBEvelyne Silva Brum
Evelyne Silva Brum
IBIndiara Brusco
Indiara Brusco
GTGabriela Trevisan
Gabriela Trevisan

11 November 2025 in Medicinal Research Reviews
Verified
Journal Article
Closed access
IBIndiara Brusco
Indiara Brusco
SOSara Marchesan Oliveira
Sara Marchesan Oliveira

17 June 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Gabriela Adriany Lisboa ZilliGabriela Adriany Lisboa Zilli
Gabriela Adriany Lisboa Zilli
SMSamara Cristina Mazon
Samara Cristina Mazon
POPatricia Viera de Oliveira
Patricia Viera de Oliveira
FZFelipe Zaniol
Felipe Zaniol
EBEulalia L. S. Barros
Eulalia L. S. Barros
IBIndiara Brusco
Indiara Brusco
Background/Objectives: Paclitaxel is a chemotherapy drug used to treat various tumours, but its use is often limited by an acute and chronic pain syndrome that is poorly managed. Naringin and its aglycone, naringenin, exhibit antioxidant, antitumour, anti-inflammatory, and antinociceptive effects, making them potential alternative treatments. However, their low water solubility limits their oral bioavailability in humans. Micronisation in a supercritical medium reduces particle size and enhances the dissolution of compounds, offering a possible solution. In this study, we investigated whether micronising naringin and naringenin via supercritical technology could improve their dissolution and oral efficacy against paclitaxel-induced pain syndrome. Methods: Micronisation was performed using supercritical CO2. Molecular docking was used to analyse the binding of naringin and naringenin to TRPV1, a key target for pain relief. Swiss mice were used in capsaicin (TRPV1 agonist)-induced nociception and paclitaxel-caused acute and chronic pain models. We assessed mechanical, cold, and heat sensitivity, potential adverse effects, and TRPV1 mRNA expression. Results: Micronisation improved the apparent dissolution profile of molecules. Docking results showed that naringin and naringenin bind to TRPV1. Both micronised compounds reduced capsaicin-induced nociception without affecting locomotion or body temperature. Micronised naringin and naringenin alleviated mechanical and cold allodynia, as well as thermal hyperalgesia in both acute and chronic paclitaxel-induced pain, outperforming their conventional forms. They also downregulated TRPV1 mRNA expression in the mice’s sciatic nerve. Conclusions: Taken together, these results show that supercritical micronisation improved the apparent dissolution and oral antinociceptive efficacy of naringin and naringenin, emphasising their potential as promising alternatives for managing paclitaxel-induced pain, with TRPV1 being a probable contributor to the observed antinociceptive effects.

3 November 2026 in Inflammopharmacology
Verified
Journal Article
Open access
PDF file
PLPatricia de Cássia Duarte Lise
Patricia de Cássia Duarte Lise
GZGabriela Adriany Lisboa Zilli
Gabriela Adriany Lisboa Zilli
HCHemyly Cardoso
Hemyly Cardoso
KBKanandra Taisa Bertoncello
Kanandra Taisa Bertoncello
GBGabriela Becker
Gabriela Becker
IBIndiara Brusco
Indiara Brusco
Fibromyalgia is a syndrome characterised by widespread chronic pain, often accompanied by comorbidities such as fatigue, anxiety, and depression. Pharmacological treatments offer only partial relief of symptoms and can cause significant adverse effects. Therefore, finding new treatments is crucial. Psychotria nemorosa , a species rich in indole alkaloids, has garnered interest due to its acute antinociceptive properties observed in vivo and its effects on monoamine oxidase A and B in in vitro assays. Additionally, alkaloids are recognised for their antinociceptive effects, as well as their anxiolytic and antidepressant properties. Therefore, we examined the effects of the alkaloid fraction of P. nemorosa in a model that simulates fibromyalgia symptoms in male Swiss. Initially, the antinociceptive effects of the fraction (3, 10, and 30 mg/kg, administered orally) were tested in capsaicin- and formalin-induced nociception, and potential adverse effects on locomotion and body temperature were evaluated. Next, the 30 mg/kg dose was tested in the reserpine-induced fibromyalgia model for mechanical, cold, and heat sensitivity, muscle strength, and behaviours resembling depression and anxiety. The P. nemorosa alkaloid fraction (30 mg/kg) decreased capsaicin- and formalin-induced nociception without affecting locomotion or body temperature. It also alleviated mechanical and cold allodynia, thermal hyperalgesia, muscle fatigue, and anxiety-like behaviour caused by reserpine, although it did not show an antidepressant-like effect. These results suggest that the P. nemorosa alkaloid fraction has therapeutic potential for treating fibromyalgia pain and related conditions such as fatigue and anxiety. They also emphasise the need for further research into its mechanisms and its long-term safety.